While we recognize that there is a need in certain situations to ensure that there is careful post-procedure monitoring following intrathecal delivery of Spinraza, this is related to the specific ...

Biogen said that new data examining of its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates that a higher dose than currently approved may lead to better ...

The CHERISH study was a multicenter, randomized, double-blind, sham-procedure controlled study to evaluate the safety and efficacy of Spinraza in children with later-onset SMA (n=126) aged 2-12 years.

Spinraza is a prescription drug used to treat spinal muscular atrophy in adults and children. Find out about cost, financial and insurance assistance, and more.

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

A carton of Spinraza, Biogen’s new treatment for spinal muscular atrophy (SMA). The first year of treatment will cost $750,000, and $375,000 per year after that.

Spinraza, which is used to treat spinal muscular atrophy, can cause side effects. Learn about its mild and serious side effects and how to manage them.

--Ionis Pharmaceuticals today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA ® in infants and toddlers living with spinal muscular atrophy ...

Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma ...

Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with ...

But in the three months since, some parents in Massachusetts have fought to get their insurer, Neighborhood Health Plan, to pay for the medicine, an enormously expensive drug called Spinraza and ...

Biogen’s SPINRAZA® Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with SMA.